Shares of 10X Genomics Inc (NASDAQ:TXG) rose 3.8% on Wednesday following disclosure of a multi-year research collaboration with the Cleveland Clinic focused on biomarker discovery in bladder cancer. The collaboration will use 10X Genomics' suite of single-cell and spatial analysis tools to investigate molecular features tied to therapeutic response.
The partnership is designed to identify biomarkers that might predict which patients respond to antibody-drug conjugates - a class of targeted therapies - by leveraging platforms from 10X Genomics, specifically Flex Apex, Xenium and the recently announced Atera platform.
Under the agreement, researchers will analyze tumor specimens from patients with advanced bladder cancer who are receiving emerging therapeutic regimens. The planned work will probe several components of the tumor ecosystem, including tumor microenvironment composition, immune cell infiltration and the expression of therapeutic targets. The stated aim is to better characterize mechanisms that underpin both sensitivity and resistance to treatments such as antibody-drug conjugates and immunotherapies.
"We look forward to collaborating with 10x Genomics on this promising work. This collaboration has the potential to shed new light into the mechanisms underlying therapeutic response in a number of major cancer types," commented Timothy Chan, MD, PhD, Chair, Department of Cancer Sciences at Cleveland Clinic.
Methodologically, the study will integrate single-cell transcriptomic profiling with spatial gene expression and protein measurements. Investigators expect this combination to produce a comprehensive dataset that links single-cell and spatial insights to clinical outcomes, enabling more nuanced correlations between molecular states and patient responses.
10X Genomics characterized the Cleveland Clinic collaboration as part of a broader strategy to work with research institutions to build the evidence base needed to support potential future diagnostic applications across oncology and other disease areas.
Context and implications
- The research aims to generate data that could inform diagnostic development tied to therapeutic selection and to elucidate biology relevant to treatment resistance.
- The project's focus on antibody-drug conjugates and immunotherapies places it squarely at the intersection of translational oncology and clinical biomarker research.
While the collaboration is described as multi-year and methodologically broad, specific timelines, sample sizes and predefined clinical endpoints were not detailed in the announcement.